Markets:

Overview

News

Currencies

International

Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.0756 -0.0025 (-3.20%)

Streaming Delayed Price Updated: 3:01 PM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pharmather Hldgs Ltd

< Previous 1 2 3 4 Next >

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

October 05, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Provides Business Highlights And Releases Audited Annual Financials ↗

September 29, 2022

PharmaTher Holdings Ltd. (OTCQB: PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.

Via Benzinga

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

September 29, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease ↗

September 17, 2022

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced...

Via Benzinga

Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies ↗

September 07, 2022

PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and...

Via Benzinga

PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment ↗

July 13, 2022

Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S.

Via Benzinga

PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing ↗

June 29, 2022

Ketamine-producer PharmaTher Holdings Ltd. (OTCQB: PHRRF) has successfully completed research evaluating its patented hydrogel-forming microneedle patch, PHARMAPATCH, to deliver ketamine and KETABET...

Via Benzinga

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry ↗

June 02, 2022

In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its...

Via Benzinga

More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO ↗

May 26, 2022

PharmaTher Holdings Ltd. (OTC: PHRRF) continues on its path to becoming the leader in specialty ketamine products.

Via Benzinga

Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs ↗

May 10, 2022

Psychedelics policy action took center stage this week.

Via Benzinga

Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process ↗

May 05, 2022

The U.S. Patent and Trademark Office has granted Pharmather Holdings Ltd. (OTCQB: PHRRF) a patent for a ketamine production process.

Via Benzinga

Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward ↗

May 02, 2022

The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.

Via Benzinga

Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy ↗

April 26, 2022

Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022.

Via Benzinga

Ketamine Could Help Treat Parkinson's Disease, Study Finds ↗

March 24, 2022

PharmaTher Holdings Ltd. (OTCQB: PHRRF) announced positive results from a clinical study of ketamine for the treatment of ...

Via Benzinga

Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022 ↗

January 25, 2022

This article was originally published on Micr...

Via Benzinga

FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment ↗

January 12, 2022

PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced...

Via Benzinga

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval ↗

November 08, 2021

Detroit Decriminalizes Psychedelics

Via Benzinga

Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program ↗

October 11, 2021

The Week In Psychedelics

Via Benzinga

Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction ↗

October 04, 2021

The Week In Psychedelics:

Via Benzinga

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts

September 22, 2021

Via FinancialNewsMedia

These OTC Securities Had the Most Trading Activity in June ↗

July 20, 2021

Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as...

Via Benzinga

Topics Cannabis

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

How To Invest In "Magic Mushrooms" (Psychedelics) ↗

July 09, 2021

A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.

Via Talk Markets

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies ↗

July 02, 2021

Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...

Via Benzinga

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More ↗

June 30, 2021

Institutional analysts are taking a liking to the industry ...

Via Benzinga

Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research ↗

May 24, 2021

MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ:

Via Benzinga

Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading ↗

April 26, 2021

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ...

Via Benzinga

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

April 14, 2021

Via FinancialNewsMedia

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.